FDA red and green lights: October 2025
Syndax’s Revuforj beats Kura in NPM1-mutated AML.
Caribou finds a match
As tinkering with HLA matching continues, is nearly as good as Breyanzi good enough?
Henlius goes on the anti-Pfizer offensive
But the extensively curated dataset covering its anti-PD-L1 ADC raises more questions.
The month ahead: November’s upcoming events
FDA decisions loom for Kura’s ziftomenib and Bayer’s sevabertinib.
